Switch to:
More From Other Websites
Why Earnings Season Could Be Great for Exelixis (EXEL) Feb 24 2017
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store? Feb 22 2017
Patterson Companies (PDCO) Q3 Earnings: What's in Store? Feb 21 2017
Forget Alexion, Buy these 4 Biotech Stocks Instead Feb 20 2017
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards? Feb 20 2017
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or... Feb 17 2017
Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint? Feb 17 2017
Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on... Feb 17 2017
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia... Feb 14 2017
Forget Gilead, Buy These 5 Biotech Stocks Instead Feb 13 2017
Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure... Feb 10 2017
Exelixis (EXEL) Shares March Higher, Can It Continue? Feb 10 2017
Harry Boxer’s stocks to watch: biotechnology and technology Feb 09 2017
Buy 4 Stocks Riding High on Superb Earnings Acceleration Feb 09 2017
5 Drug Stocks Poised to Beat Earnings Estimates in Q4 Feb 09 2017
Four Biotech Stocks Breaking Out Feb 08 2017
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma Feb 08 2017
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis... Feb 08 2017
Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15 Feb 07 2017
5 Great Biotech Stocks to Buy Now Feb 07 2017
Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel... Jan 30 2017
Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel... Jan 30 2017
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 03 2017
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of... Dec 21 2016
Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of... Dec 21 2016
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of... Dec 21 2016
Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of... Dec 21 2016
Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate... Nov 03 2016
Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate... Nov 03 2016
Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016 Oct 20 2016
Exelixis and Pfizer drugs compete in kidney cancer trial Oct 10 2016
Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in... Oct 10 2016
Exelixis and Pfizer drugs face off in kidney cancer Oct 10 2016
Ipsens’ partner, Exelixis, Announced Phase 1 Trial Results for Cabozantinib in Combination with... Oct 07 2016
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced... Oct 07 2016
Exelixis Elects Julie Anne Smith to Its Board of Directors Sep 26 2016
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for... Sep 26 2016
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for... Sep 26 2016
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal... Sep 14 2016
Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of... Sep 06 2016
Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019 Aug 24 2016
Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate... Aug 03 2016
Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the... Jul 22 2016
Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the... Jul 22 2016
Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016 Jul 12 2016
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of... Jun 06 2016
US stocks flat as Lockheed Martin seals Sikorsky deal Jul 20 2015
Roche open to alliances in hunt for cancer drug combinations Apr 01 2015
BUZZ-U.S. STOCKS ON THE MOVE-Wal-Mart, Priceline, Ocera Therapeutics, Netlist Feb 19 2015
US STOCKS-Wall St set for flat open; manufacturing data on tap Sep 02 2014
US STOCKS-Futures inch higher ahead of manufacturing data Sep 02 2014
Exelixis to cut jobs after prostate cancer drug fails late-stage study Sep 01 2014


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK